Cita APA

Tibau, A., Martínez, M. T., Ramos, M., Cruz Merino, L. d. l., Santaballa, A., O’Connor, M., & Albanell, J. (2023). Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: Patient-reported outcomes from the FLIPPER trial.

Citación estilo Chicago

Tibau, Ariadna, M. Teresa Martínez, Manuel Ramos, Luis de la Cruz Merino, Ana Santaballa, Miriam O’Connor, y Joan Albanell. Quality of Life With Palbociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Endocrine-sensitive Hormone Receptor-positive and HER2-negative Advanced Breast Cancer: Patient-reported Outcomes From the FLIPPER Trial. 2023.

Cita MLA

Tibau, Ariadna, et al. Quality of Life With Palbociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Endocrine-sensitive Hormone Receptor-positive and HER2-negative Advanced Breast Cancer: Patient-reported Outcomes From the FLIPPER Trial. 2023.